IgA肾病中尿蛋白早期变化与GFR斜率治疗效应的个体参与者荟萃分析
该个体患者水平荟萃分析纳入12项随机试验的1037例IgA肾病患者,评估治疗对蛋白尿早期变化与eGFR斜率的影响。贝叶斯混合效应分析显示,蛋白尿治疗效应对3年总斜率和慢性斜率具有高度预测性(中位R²分别为0.88和0.98)。约30%的蛋白尿降低可赋予总斜率和慢性斜率非零治疗获益至少90%的概率。
要点
- 蛋白尿早期变化可准确预测IgA肾病eGFR总斜率和慢性斜率的治疗效应。
- 约30%的蛋白尿降低对应eGFR斜率非零获益概率至少90%。
- 结果支持蛋白尿早期降低作为IgA肾病进展的替代终点。
核心结论
- 早期蛋白尿降低可作为IgA肾病慢性肾脏病进展研究的替代终点。
研究设计与样本
- 个体患者水平荟萃分析,纳入12项随机试验共1037例IgA肾病患者。
主要发现
- 蛋白尿治疗效应对3年总斜率预测中位R²=0.88(95% BCI 0.06-1),对慢性斜率R²=0.98(95% BCI 0.29-1)。
- 约30%的蛋白尿降低赋予总斜率和慢性斜率非零治疗获益至少90%的概率。
- 9个月和12个月蛋白尿及2年总斜率结果相似。
临床怎么用
- 在IgA肾病临床试验中,可采用早期蛋白尿降低作为加速审批的替代终点,并以eGFR斜率验证。
局限性
- 研究人群限于12项小样本试验,导致贝叶斯可信区间宽。
- 试验间在设计及干预措施方面存在异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: An early change in proteinuria is considered a reasonably likely surrogate end point in immunoglobulin A nephropathy (IgAN) and can be used as a basis for accelerated approval of therapies, with verification in a postmarketing confirmatory trial. Glomerular filtration rate (GFR) slope is a recently validated surrogate end point for chronic kidney disease progression and may be considered as the end point used for verification. We undertook a meta-analysis of clinical trials in IgAN to compare treatment effects on change in proteinuria versus change in estimated GFR (eGFR) slope. STUDY DESIGN: Individual patient-level meta-analysis. SETTING & STUDY POPULATIONS: Individual data of 1,037 patients from 12 randomized trials. SELECTION CRITERIA FOR STUDIES: Randomized trials of IgAN with proteinuria measurements at baseline and 6 (range, 2.5-14) months and at least a further 1 year of follow-up for the clinical outcome. ANALYTICAL APPROACH: For each trial, we estimated the treatment effects on proteinuria and on the eGFR slope, computed as the total slope starting at baseline or the chronic slope starting 3 months after randomization. We used a Bayesian mixed-effects analysis to relate the treatment effects on proteinuria to effects on GFR slope across these studies and developed a prediction model for the treatment effect on the GFR slope based on the effect on proteinuria. RESULTS: Across all studies, treatment effects on proteinuria accurately predicted treatment effects on the total slope at 3 years (median R2 = 0.88; 95% Bayesian credible interval [BCI], 0.06-1) and on the chronic slope (R2 = 0.98; 95% BCI, 0.29-1). For future trials, an observed treatment effect of approximately 30% reduction in proteinuria would confer probabilities of at least 90% for nonzero treatment benefits on the total and chronic slopes of eGFR. We obtained similar results for proteinuria at 9 and 12 months and total slope at 2 years. LIMITATIONS: Study population restricted to 12 trials of small sample size, leading to wide BCIs. There was heterogeneity among trials with respect to study design and interventions. CONCLUSIONS: These results provide new evidence supporting that early reduction in proteinuria can be used as a surrogate end point for studies of chronic kidney disease progression in IgAN.
引用
- Inker LA, Heerspink HJL, Tighiouart H, et al. Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis. Am J Kidney Dis. 2021. PMID: 33775708. doi:10.1053/j.ajkd.2021.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。